Enhancing CRISPR-based therapeutics with composite purity analysis of sgRNA
Explore how Synthego is using multiple methods to detect and resolve impurities in synthetic single guide RNAs to make your CRISPR therapeutic journey more successful.
CRISPR-associated sgRNA can often require long (100+ bases) synthetic nucleic acids as part of the therapeutic product. The accurate measurement and identification of the Full Length Product and its related impurities is required in order to satisfy regulatory guidelines. We will be presenting work describing the use of complementary techniques, such as LC-UV, ESI-MS and others, to accurately characterize the sgRNA profile. Understanding and resolving impurities is essential to making high-quality sgRNAs fit for IND-enabling studies and clinical trials.
This webinar is produced in association with Synthego Corporation.
This webinar was recorded on 14 November 2023.
What will you learn?
- How Synthego is using orthogonal methods to resolve impurities in clinical-grade sgRNAs
- Why impurity resolution is critical for gRNAs at all stages during the development of CRISPR-based therapeutics
- How Synthego’s full continuum of gRNA products and services supports a seamless transition from discovery to delivery
Who may this interest?
- Researchers using CRISPR to develop cell and gene therapies
- Researchers looking for high-quality sgRNAs for IND-enabling studies
- Researchers looking for GMP-grade sgRNAs for clinical trials
Speaker
John Walker
Vice President, Chemical Sciences
Synthego (CA, USA)
Johnnie Walker received his doctorate in Medicinal Chemistry from the University of Michigan (MI, USA) in 1997. His career has touched many areas within the protein and nucleic acid research fields. Since 2015, Dr Walker has been passionately leading Synthego’s Chemistry teams and achieving the company goal of faster CRISPR results.
In association with
